AAV Constructs with Nrf2 Expression for Retinal Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Intraocular delivery of adeno-associated viruses (AAVs) commonly used for retinal disorders induces cone outer segment shortening and retinal pigment epithelial toxicity, which is correlated with AAV vector/construct structure, necessitating the development of AAV constructs that reduce toxicity while maintaining pharmacological activity for treating degenerative ocular diseases like retinitis pigmentosa.
Innovation Solution
The development of AAV expression cassettes comprising a human bestrophin 1 promoter, a chimeric intron, and a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2), which are incorporated into AAV vectors to reduce toxicity and enhance therapeutic efficacy for treating degenerative ocular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If commonly used AAV vectors are delivered intraocularly for treating retinal disorders, then gene therapy efficacy is achieved, but cone outer segment shortening and retinal pigment epithelial toxicity occur
Solution Approach 1:
The patent modifies the AAV vector construct parameters by optimizing the promoter region, adding specific regulatory elements, and adjusting the capsid composition to reduce retinal toxicity while preserving gene therapy efficacy. This involves changing the molecular structure and expression characteristics of the viral vector.
Solution Approach 2:
The patent identifies and removes or reduces the concentration of toxic components within the AAV vector construct, such as harmful viral proteins or excessive expression levels of certain genes, while retaining the essential therapeutic functions.
2Object-affected harmful factors
If AAV vector construct structure is modified to reduce toxicity, then retinal safety is improved, but pharmacological activity may be compromised
Solution Approach 1:
The patent systematically adjusts multiple parameters of the AAV construct including promoter strength, gene expression levels, and vector composition to find an optimal balance that minimizes toxicity while maintaining sufficient pharmacological activity for therapeutic effect.
Solution Approach 2:
The patent uses controlled expression levels where moderate or partial expression of certain genes provides sufficient therapeutic benefit without reaching the threshold that causes toxicity, effectively using 'less is more' approach for certain vector components.
3Productivity
If high dose AAV is administered to ensure therapeutic effect, then gene delivery efficiency increases, but retinal toxicity is exacerbated
Solution Approach 1:
The patent enhances the intrinsic delivery efficiency of the AAV vector through capsid engineering and construct optimization, allowing effective gene delivery at lower doses thereby avoiding the toxicity associated with high dose administration.
Data Source
AI summary
The present invention provides compositions, e.g., pharmaceutical compositions, which include a recombinant adeno-associated viral (AAV) expression construct, AAV vectors, AAV particles, and methods of treating a subject having a degenerative ocular disorder, e.g., retinitis pigmentosa.